<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00330863</url>
  </required_header>
  <id_info>
    <org_study_id>U01MH070007-01</org_study_id>
    <secondary_id>U01MH070007-01</secondary_id>
    <secondary_id>U01MH070023</secondary_id>
    <secondary_id>U01MH070011</secondary_id>
    <secondary_id>U01MH070009</secondary_id>
    <secondary_id>U01MH070008</secondary_id>
    <secondary_id>U01MH070017</secondary_id>
    <secondary_id>U01MH070010</secondary_id>
    <secondary_id>U01MH070016</secondary_id>
    <secondary_id>U01MH070012</secondary_id>
    <secondary_id>DSIR 83-ATAP</secondary_id>
    <nct_id>NCT00330863</nct_id>
  </id_info>
  <brief_title>Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy</brief_title>
  <acronym>PROACTIVE</acronym>
  <official_title>Preventing Relapse: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy (PROACTIVE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwell Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwell Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to find out whether taking antipsychotic medication once every two
      weeks by injection compared to taking daily oral medication will help people with
      schizophrenia maintain better control of their symptoms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As is the case with many chronic illnesses, it can be challenging for people with
      schizophrenia to take multiple pills every day on a long-term basis. At the same time,
      missing or discontinuing the anti-psychotic medications that treat schizophrenia
      substantially increases the risk of relapse and re-hospitalization. This study will determine
      how effective long-acting injectable risperidone is compared to oral antipsychotic
      medications to help patients who have schizophrenia. Patients who enroll in the study will be
      randomly assigned to receive either long-acting injectable risperidone or to receive oral
      &quot;atypical&quot; antipsychotic medication. The &quot;atypical&quot; antipsychotics that are included for
      patients in the oral group are: aripiprazole, olanzapine, quetiapine, risperidone, and
      ziprasidone. Patients in the &quot;oral&quot; group will receive whichever of the five &quot;atypical&quot;
      antipsychotic medications they and their study doctor decide is best for them. Patients in
      the &quot;oral&quot; group will be allowed to switch to others of the five medications during the study
      if they and their doctor think that is best.

      Patients in this study will be evaluated at the beginning of the study and then again every
      two weeks for up to 30 months (2 1/2 years). Each two-week visit will take about 20 minutes.
      At the visit, patients will receive medication and will be examined for side effects of the
      medications, their vital signs (heart rate, blood pressure, weight, and waist measurement)
      will be measured, and they will be asked a few questions about attendance at visits and
      taking medication. The visit that occurs every three months will take about one hour, instead
      of 20 minutes, and will include additional questions, an examination for muscle stiffness or
      abnormal body movements, and an interview from a member of the research team conducted using
      computer technology. In addition, blood and urine samples may be collected about seven times
      throughout the 30 months of the study treatment. Patients who enroll in this study after the
      halfway point of the study, may not receive a full 30 months of treatment, but it is planned
      that all patients will have the opportunity to receive no less than 18 months of treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Substantial Clinical Deterioration Measured by Psychotic Symptoms</measure>
    <time_frame>Measured throughout study up to 30 months</time_frame>
    <description>Brief Psychiatric Rating Scale (BPRS) psychosis cluster. Score range is based on the score range for individual items rather than the factor total because is factors have different numbers of items. Score range is 1 -7 where 1 + no symptomatology and 7 = very severe symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Discontinuing From the Study</measure>
    <time_frame>Measured throughout study up to 30 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days in Hospital</measure>
    <time_frame>Measured throughout study up to 30 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Control of Psychiatric Symptoms</measure>
    <time_frame>Measured throughout study up to 30 months</time_frame>
    <description>Brief Psychiatric Rating Scale (BPRS) total score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Measures</measure>
    <time_frame>Measured throughout study up to 30 months</time_frame>
    <description>Scale of Functioning (SOF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side Effects and Metabolic Measures</measure>
    <time_frame>Measured throughout study up to 30 months</time_frame>
    <description>The highest severity of each of 24 adverse event (AE) that was assessed.over the 30 month study period. The mean severity on a scale of 1 (none) to 4 very severe symptom was recorded at each biweekly visit. Results for each variable are summarized over time so that each subject has a single mean severity rating for each AE. There is no named scale. Each of the side effects measured is named in ways that are clear to medical readers e.g anorexia. The range is 1 none to 4 very severe. Therefore, a higher scale score is worse.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">357</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Schizoaffective Disorder</condition>
  <arm_group>
    <arm_group_label>Injectable</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants assigned to receive long-acting injectable risperidone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants assigned to receive oral &quot;atypical&quot; antipsychotic medication</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risperidone microspheres</intervention_name>
    <description>Minimum dose is 12.5 mg every 2 weeks. Maximum dose is 75 mg every 2 weeks.</description>
    <arm_group_label>Injectable</arm_group_label>
    <other_name>Risperdal Consta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risperidone</intervention_name>
    <description>Target dose is 4 mg/day.</description>
    <arm_group_label>Oral</arm_group_label>
    <other_name>Risperdal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olanzapine</intervention_name>
    <description>Target dose is 15 mg/day.</description>
    <arm_group_label>Oral</arm_group_label>
    <other_name>Zyprexa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quetiapine</intervention_name>
    <description>Target dose is 600 mg/day.</description>
    <arm_group_label>Oral</arm_group_label>
    <other_name>Seroquel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ziprasidone</intervention_name>
    <description>Target dose is 120 mg/day.</description>
    <arm_group_label>Oral</arm_group_label>
    <other_name>Geodon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aripiprazole</intervention_name>
    <description>Target dose is 20 mg/day.</description>
    <arm_group_label>Oral</arm_group_label>
    <other_name>Abilify</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paliperidone</intervention_name>
    <description>Target dose is 6 mg/day.</description>
    <arm_group_label>Oral</arm_group_label>
    <other_name>Invega</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All schizophrenia and schizoaffective patients whose clinicians are considering
             long-term treatment with an &quot;atypical&quot; (second generation) antipsychotic medication

          -  Worsening of illness (schizophrenia) within 12 months of study entry as defined by:
             hospitalization, increased level of clinical care, and/or present clinical Global
             Impressions Severity rating of moderate or worse

        Exclusion Criteria:

          -  First episode patients as defined by a patient who: has never received antipsychotic
             medication and has never been hospitalized for psychiatric illness; or, is receiving
             antipsychotic medication for the first time associated with a first diagnosis of
             schizophrenia.

          -  Pregnant or breastfeeding

          -  Patients with unstable medical conditions

          -  Patients with previous history of failure to respond to an adequate trial of clozapine

          -  Patients with a known allergy to risperidone or a previous history of failure to
             respond to an adequate trial of risperidone. However, patients with known allergies or
             failure to respond to any of the other medications (aripiprazole, olanzapine,
             quetiapine or ziprasidone) will not receive that medication if they are randomized to
             the oral medication arm, but are not excluded from the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nina R. Schooler, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Steering and Implementation Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>91344</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Georgia, Department of Psychiatry</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912-3800</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa College of Medicine, Psychiatry Research</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harvard Medical School -- Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harvard Medical School -- Dr. John C. Corrigan Community Mental Health Center</name>
      <address>
        <city>Fall River</city>
        <state>Massachusetts</state>
        <zip>02720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Creighton University</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Zucker Hillside Hospital</name>
      <address>
        <city>Glen Oaks</city>
        <state>New York</state>
        <zip>11004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Buckley PF, Schooler NR, Goff DC, Hsiao J, Kopelowicz A, Lauriello J, Manschreck T, Mendelowitz AJ, Miller del D, Severe JB, Wilson DR, Ames D, Bustillo J, Mintz J, Kane JM; PROACTIVE Study. Comparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE study. Schizophr Bull. 2015 Mar;41(2):449-59. doi: 10.1093/schbul/sbu067. Epub 2014 May 27.</citation>
    <PMID>24870446</PMID>
  </results_reference>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>May 26, 2006</study_first_submitted>
  <study_first_submitted_qc>May 26, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2006</study_first_posted>
  <results_first_submitted>September 4, 2015</results_first_submitted>
  <results_first_submitted_qc>June 12, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">July 10, 2018</results_first_posted>
  <last_update_submitted>June 12, 2018</last_update_submitted>
  <last_update_submitted_qc>June 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relapse</keyword>
  <keyword>Prevention</keyword>
  <keyword>Schizophrenia</keyword>
  <keyword>Injectable Medication</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olanzapine</mesh_term>
    <mesh_term>Risperidone</mesh_term>
    <mesh_term>Aripiprazole</mesh_term>
    <mesh_term>Quetiapine Fumarate</mesh_term>
    <mesh_term>Paliperidone Palmitate</mesh_term>
    <mesh_term>Ziprasidone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>357 individuals consented to participation. However, 52 were either ineligible, withdrew consent, or lost to followup. Therefore, 305 individuals were randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Injectable</title>
          <description>Participants assigned to receive long-acting injectable risperidone
Risperidone microspheres: Minimum dose is 12.5 mg every 2 weeks. Maximum dose is 75 mg every 2 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Oral</title>
          <description>Participants assigned to receive oral &quot;atypical&quot; antipsychotic medication
Risperidone: Target dose is 4 mg/day.
Olanzapine: Target dose is 15 mg/day.
Quetiapine: Target dose is 600 mg/day.
Ziprasidone: Target dose is 120 mg/day.
Aripiprazole: Target dose is 20 mg/day.
Paliperidone: Target dose is 6 mg/day.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="153"/>
                <participants group_id="P2" count="152"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="72"/>
                <participants group_id="P2" count="72"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="81"/>
                <participants group_id="P2" count="80"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Injectable</title>
          <description>Participants assigned to receive long-acting injectable risperidone
Risperidone microspheres: Minimum dose is 12.5 mg every 2 weeks. Maximum dose is 75 mg every 2 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Oral</title>
          <description>Participants assigned to receive oral &quot;atypical&quot; antipsychotic medication
Risperidone: Target dose is 4 mg/day.
Olanzapine: Target dose is 15 mg/day.
Quetiapine: Target dose is 600 mg/day.
Ziprasidone: Target dose is 120 mg/day.
Aripiprazole: Target dose is 20 mg/day.
Paliperidone: Target dose is 6 mg/day.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="153"/>
            <count group_id="B2" value="152"/>
            <count group_id="B3" value="305"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.18" spread="11.8"/>
                    <measurement group_id="B2" value="38.23" spread="12.3"/>
                    <measurement group_id="B3" value="38.2" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="87"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="108"/>
                    <measurement group_id="B2" value="110"/>
                    <measurement group_id="B3" value="218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="153"/>
                    <measurement group_id="B2" value="152"/>
                    <measurement group_id="B3" value="305"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Clinical Global Impressions (CGI) Severity Scale</title>
          <description>The Clinical Global Impressions Severity Scale is one item completed by a clinician rater. &quot;Considering your total clinical experience with this patient population, how mentally ill is the patient at this time?&quot; The seven possible ratings are as follows.
= Normal, not at all.
= Borderline mentally ill.
= Mildly ill.
= Moderately ill.
= Markedly ill.
= Severely ill
= Among the most extremely ill patients.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.1" spread="0.84"/>
                    <measurement group_id="B2" value="4.0" spread="0.77"/>
                    <measurement group_id="B3" value="4.04" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Substantial Clinical Deterioration Measured by Psychotic Symptoms</title>
        <description>Brief Psychiatric Rating Scale (BPRS) psychosis cluster. Score range is based on the score range for individual items rather than the factor total because is factors have different numbers of items. Score range is 1 -7 where 1 + no symptomatology and 7 = very severe symptoms.</description>
        <time_frame>Measured throughout study up to 30 months</time_frame>
        <population>We conducted a mixed model regression analysis with two treatment groups X time psychosis cluster scores at each 3 monthly observation from baseline to 30 months. Missing data were treated as MAR</population>
        <group_list>
          <group group_id="O1">
            <title>Injectable</title>
            <description>Participants assigned to receive long-acting injectable risperidone
Risperidone microspheres: Minimum dose is 12.5 mg every 2 weeks. Maximum dose is 75 mg every 2 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Oral</title>
            <description>Participants assigned to receive oral &quot;atypical&quot; antipsychotic medication
Risperidone: Target dose is 4 mg/day.
Olanzapine: Target dose is 15 mg/day.
Quetiapine: Target dose is 600 mg/day.
Ziprasidone: Target dose is 120 mg/day.
Aripiprazole: Target dose is 20 mg/day.
Paliperidone: Target dose is 6 mg/day.</description>
          </group>
        </group_list>
        <measure>
          <title>Substantial Clinical Deterioration Measured by Psychotic Symptoms</title>
          <description>Brief Psychiatric Rating Scale (BPRS) psychosis cluster. Score range is based on the score range for individual items rather than the factor total because is factors have different numbers of items. Score range is 1 -7 where 1 + no symptomatology and 7 = very severe symptoms.</description>
          <population>We conducted a mixed model regression analysis with two treatment groups X time psychosis cluster scores at each 3 monthly observation from baseline to 30 months. Missing data were treated as MAR</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="1.7" upper_limit="1.9"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.9" upper_limit="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Discontinuing From the Study</title>
        <time_frame>Measured throughout study up to 30 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Injectable</title>
            <description>Participants assigned to receive long-acting injectable risperidone
Risperidone microspheres: Minimum dose is 12.5 mg every 2 weeks. Maximum dose is 75 mg every 2 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Oral</title>
            <description>Participants assigned to receive oral &quot;atypical&quot; antipsychotic medication
Risperidone: Target dose is 4 mg/day.
Olanzapine: Target dose is 15 mg/day.
Quetiapine: Target dose is 600 mg/day.
Ziprasidone: Target dose is 120 mg/day.
Aripiprazole: Target dose is 20 mg/day.
Paliperidone: Target dose is 6 mg/day.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Discontinuing From the Study</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days in Hospital</title>
        <time_frame>Measured throughout study up to 30 months</time_frame>
        <population>These data were not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Injectable</title>
            <description>Participants assigned to receive long-acting injectable risperidone
Risperidone microspheres: Minimum dose is 12.5 mg every 2 weeks. Maximum dose is 75 mg every 2 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Oral</title>
            <description>Participants assigned to receive oral &quot;atypical&quot; antipsychotic medication
Risperidone: Target dose is 4 mg/day.
Olanzapine: Target dose is 15 mg/day.
Quetiapine: Target dose is 600 mg/day.
Ziprasidone: Target dose is 120 mg/day.
Aripiprazole: Target dose is 20 mg/day.
Paliperidone: Target dose is 6 mg/day.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days in Hospital</title>
          <population>These data were not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Control of Psychiatric Symptoms</title>
        <description>Brief Psychiatric Rating Scale (BPRS) total score</description>
        <time_frame>Measured throughout study up to 30 months</time_frame>
        <population>These data were not collected. No data displayed because Outcome Measure has zero total participants analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Injectable</title>
            <description>Participants assigned to receive long-acting injectable risperidone
Risperidone microspheres: Minimum dose is 12.5 mg every 2 weeks. Maximum dose is 75 mg every 2 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Oral</title>
            <description>Participants assigned to receive oral &quot;atypical&quot; antipsychotic medication
Risperidone: Target dose is 4 mg/day.
Olanzapine: Target dose is 15 mg/day.
Quetiapine: Target dose is 600 mg/day.
Ziprasidone: Target dose is 120 mg/day.
Aripiprazole: Target dose is 20 mg/day.
Paliperidone: Target dose is 6 mg/day.</description>
          </group>
        </group_list>
        <measure>
          <title>Control of Psychiatric Symptoms</title>
          <description>Brief Psychiatric Rating Scale (BPRS) total score</description>
          <population>These data were not collected. No data displayed because Outcome Measure has zero total participants analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Measures</title>
        <description>Scale of Functioning (SOF)</description>
        <time_frame>Measured throughout study up to 30 months</time_frame>
        <population>No data displayed because Outcome Measure has zero total participants analyzed. Data not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Injectable</title>
            <description>Participants assigned to receive long-acting injectable risperidone
Risperidone microspheres: Minimum dose is 12.5 mg every 2 weeks. Maximum dose is 75 mg every 2 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Oral</title>
            <description>Participants assigned to receive oral &quot;atypical&quot; antipsychotic medication
Risperidone: Target dose is 4 mg/day.
Olanzapine: Target dose is 15 mg/day.
Quetiapine: Target dose is 600 mg/day.
Ziprasidone: Target dose is 120 mg/day.
Aripiprazole: Target dose is 20 mg/day.
Paliperidone: Target dose is 6 mg/day.</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Measures</title>
          <description>Scale of Functioning (SOF)</description>
          <population>No data displayed because Outcome Measure has zero total participants analyzed. Data not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Side Effects and Metabolic Measures</title>
        <description>The highest severity of each of 24 adverse event (AE) that was assessed.over the 30 month study period. The mean severity on a scale of 1 (none) to 4 very severe symptom was recorded at each biweekly visit. Results for each variable are summarized over time so that each subject has a single mean severity rating for each AE. There is no named scale. Each of the side effects measured is named in ways that are clear to medical readers e.g anorexia. The range is 1 none to 4 very severe. Therefore, a higher scale score is worse.</description>
        <time_frame>Measured throughout study up to 30 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Injectable</title>
            <description>Participants assigned to receive long-acting injectable risperidone
Risperidone microspheres: Minimum dose is 12.5 mg every 2 weeks. Maximum dose is 75 mg every 2 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Oral</title>
            <description>Participants assigned to receive oral &quot;atypical&quot; antipsychotic medication
Risperidone: Target dose is 4 mg/day.
Olanzapine: Target dose is 15 mg/day.
Quetiapine: Target dose is 600 mg/day.
Ziprasidone: Target dose is 120 mg/day.
Aripiprazole: Target dose is 20 mg/day.
Paliperidone: Target dose is 6 mg/day.</description>
          </group>
        </group_list>
        <measure>
          <title>Side Effects and Metabolic Measures</title>
          <description>The highest severity of each of 24 adverse event (AE) that was assessed.over the 30 month study period. The mean severity on a scale of 1 (none) to 4 very severe symptom was recorded at each biweekly visit. Results for each variable are summarized over time so that each subject has a single mean severity rating for each AE. There is no named scale. Each of the side effects measured is named in ways that are clear to medical readers e.g anorexia. The range is 1 none to 4 very severe. Therefore, a higher scale score is worse.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bruising easily</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.43" spread="0.71"/>
                    <measurement group_id="O2" value="1.48" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.53" spread="0.78"/>
                    <measurement group_id="O2" value="1.44" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urticaria (hives, itching)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.60" spread="0.69"/>
                    <measurement group_id="O2" value="1.71" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blurred vision</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.76" spread="0.73"/>
                    <measurement group_id="O2" value="1.91" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sedation/drowsiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.34" spread="0.87"/>
                    <measurement group_id="O2" value="2.53" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Restlessness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.48" spread="0.76"/>
                    <measurement group_id="O2" value="2.43" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insomnia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.38" spread="0.89"/>
                    <measurement group_id="O2" value="2.36" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise (weakness, fatigue)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.22" spread="0.85"/>
                    <measurement group_id="O2" value="2.14" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stiffness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.01" spread="0.82"/>
                    <measurement group_id="O2" value="1.97" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tremor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.77" spread="0.72"/>
                    <measurement group_id="O2" value="1.75" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dizziness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.82" spread="0.79"/>
                    <measurement group_id="O2" value="1.78" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.99" spread="0.88"/>
                    <measurement group_id="O2" value="1.89" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.27" spread="0.49"/>
                    <measurement group_id="O2" value="1.24" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sore Throat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.64" spread="0.78"/>
                    <measurement group_id="O2" value="1.57" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dry Mouth</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.36" spread="0.92"/>
                    <measurement group_id="O2" value="2.25" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypersalivation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.76" spread="0.80"/>
                    <measurement group_id="O2" value="1.84" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Enuresis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.63" spread="0.89"/>
                    <measurement group_id="O2" value="1.56" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Constipation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.75" spread="0.86"/>
                    <measurement group_id="O2" value="1.64" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.65" spread="0.86"/>
                    <measurement group_id="O2" value="1.68" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anorexia (loss of appetite)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.89" spread="0.86"/>
                    <measurement group_id="O2" value="1.69" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.78" spread="0.82"/>
                    <measurement group_id="O2" value="1.72" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.48" spread="0.72"/>
                    <measurement group_id="O2" value="1.51" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Menstrual Irregularity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.62" spread="0.96"/>
                    <measurement group_id="O2" value="1.55" spread="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Breast tenderness/galactorrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.39" spread="0.69"/>
                    <measurement group_id="O2" value="1.32" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>305 participants were randomized. However, 9 never received study medication. Therefore, SAE results are reported for 296 participants. 5 subjects did not have postbaseline AE ratings, and therefore AE results are reported for 291 participants.</desc>
      <group_list>
        <group group_id="E1">
          <title>Injectable</title>
          <description>Participants assigned to receive long-acting injectable risperidone
Risperidone microspheres: Minimum dose is 12.5 mg every 2 weeks. Maximum dose is 75 mg every 2 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Oral</title>
          <description>Participants assigned to receive oral &quot;atypical&quot; antipsychotic medication
Risperidone: Target dose is 4 mg/day.
Olanzapine: Target dose is 15 mg/day.
Quetiapine: Target dose is 600 mg/day.
Ziprasidone: Target dose is 120 mg/day.
Aripiprazole: Target dose is 20 mg/day.
Paliperidone: Target dose is 6 mg/day.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>first relapse often hospitalization</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="143" subjects_at_risk="143"/>
                <counts group_id="E2" subjects_affected="148" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>anorexia</sub_title>
                <description>Anorexia was higher in injectable arm than in oral arm.</description>
                <counts group_id="E1" subjects_affected="143" subjects_at_risk="143"/>
                <counts group_id="E2" subjects_affected="148" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Peter F. Buckley, MD</name_or_title>
      <organization>Medical College of Georgia, Georgia Regents University</organization>
      <phone>706-721-2231</phone>
      <email>pbuckley@gru.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

